Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Alberts

Showing results (91-100 of 184) with videos related to

Pageof 19
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|May 4, 2016
Association between Circulating Vitamin D Metabolites and Fecal Bile Acid ConcentrationsElizabeth T Jacobs, Mark R Haussler, David S Alberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group studyRobert C Young, Mark F Brady, Roberta K Nieberg, et al.
Gynecologic Oncology|October 24, 2007
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)David S Alberts, P Y Liu, Sharon P Wilczynski, et al.
Analytical and Quantitative Cytology and Histology|October 2, 2004
Preneoplastic changes in ovarian tissuesMolly A Brewer, James Ranger-Moore, Mark H Greene, et al.
Breast Cancer Research and Treatment|January 7, 2009
Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six monthsDenise H Frank, Bruce F Kimler, Carol J Fabian, et al.
Plos One|April 27, 2018
Celecoxib use and circulating oxylipins in a colon polyp prevention trialJessica A Martinez, Jun Yang, Betsy C Wertheim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesisJohn L Clifford, Eugene Walch, Xiulan Yang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 20, 2004
Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trialDenise H Frank, Denise J Roe, H-H Sherry Chow, et al.
Gynecologic Oncology|January 2, 2010
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trialMaurie Markman, James Moon, Sharon Wilczynski, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 4, 2011
Nuclear morphometry identifies a distinct aggressive cellular phenotype in cutaneous squamous cell carcinomaEvan S Glazer, Peter H Bartels, Anil R Prasad, et al.
Pageof 19

Showing results (91-100 of 184) with videos related to

Sort By:
Pageof 19
Cancer Prevention Research (Philadelphia, Pa.)|May 4, 2016
Association between Circulating Vitamin D Metabolites and Fecal Bile Acid ConcentrationsElizabeth T Jacobs, Mark R Haussler, David S Alberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group studyRobert C Young, Mark F Brady, Roberta K Nieberg, et al.
Gynecologic Oncology|October 24, 2007
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)David S Alberts, P Y Liu, Sharon P Wilczynski, et al.
Analytical and Quantitative Cytology and Histology|October 2, 2004
Preneoplastic changes in ovarian tissuesMolly A Brewer, James Ranger-Moore, Mark H Greene, et al.
Breast Cancer Research and Treatment|January 7, 2009
Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six monthsDenise H Frank, Bruce F Kimler, Carol J Fabian, et al.
Plos One|April 27, 2018
Celecoxib use and circulating oxylipins in a colon polyp prevention trialJessica A Martinez, Jun Yang, Betsy C Wertheim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesisJohn L Clifford, Eugene Walch, Xiulan Yang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 20, 2004
Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trialDenise H Frank, Denise J Roe, H-H Sherry Chow, et al.
Gynecologic Oncology|January 2, 2010
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trialMaurie Markman, James Moon, Sharon Wilczynski, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 4, 2011
Nuclear morphometry identifies a distinct aggressive cellular phenotype in cutaneous squamous cell carcinomaEvan S Glazer, Peter H Bartels, Anil R Prasad, et al.
Pageof 19